Computational discovery of lead compounds targeting G1202R-based ALK triple mutations conferring lorlatinib resistance in EML4-ALK variant 3 non-small cell lung cancer

Journal of Applied Pharmaceutical Science 2026 Open access

Read full text

Authors: Palani Bharath, Sivaprakasam Vignesh, Thirumal Kumar D

DOI: 10.7324/japs.2026.264285

Cited by: 0

Fields of Study & Subjects

Computational Drug Discovery Methods Lung Cancer Treatments and Mutations Cholinesterase and Neurodegenerative Diseases